Halozyme Therapeutics, Inc.

NASDAQ: HALO
$37.76
-$0.66 (-1.7%)
Closing price October 15, 2021
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an...
As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the new Trump...
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
These biotech companies stood out from the rest with big moves over the course of the past week.
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.
Wednesday's top analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Monsanto and Virgin America.
Source: ThinkstockInvestors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts of risks, making and...
Stocks are looking for their footing after having hit new all-time highs in the prior week. Volatility has returned, but investors are looking at individual stock picks rather than just trying to...